Skip to main content Accessibility help
×
Home

Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012–2016

  • A. MÖHL (a1), L. GRÄFE (a2), C. HELMEKE (a2), D. ZIEHM (a1), M. MONAZAHIAN (a1), H.-M. IRMSCHER (a2) and J. DREESMAN (a1)...

Summary

Influenza vaccine effectiveness (VE) has to be estimated anew for every season to explore vaccines’ protective effect in the population. We report VE estimates against laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2) and influenza B among children aged 2–17 years, using test-negative design. Pooled data from two German federal states’ surveillance systems for acute respiratory illness from week 40/2012 to 20/2016 was used, yielding a total of 10 627 specimens. Odds ratios and 95% confidence intervals (95% CIs) for the association between laboratory-confirmed influenza and vaccination status were calculated by multivariate logistic regression adjusting for age, sex, illness onset and federal state. VE was estimated as 1-Odds Ratio. Overall adjusted VE was 33% (95% CI: 24·3–40·7). A strong variation of VE between the seasons and subtypes was observed: highest season- and subtype-specific VE of 86·2% (95% CI: 41·3–96·7) was found against A(H1N1)pdm09 in 7–17-year-olds in 2015/16. Low estimates of VE were observed against A(H3N2) in any season, e.g. 1·5% (95% CI: −39·3–30·3) in 2014/15. Estimates showed a tendency to higher VE among 7–17-year-old children, but differences were not statistically significant. Although our findings are common in studies estimating influenza VE, we discussed several explanations for observed low VE.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012–2016
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012–2016
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012–2016
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Annika Möhl, Wilde Heide 4, 21220 Seevetal, Germany. (Email: annikamoehl@freenet.de)

References

Hide All
1. World Health Organization (WHO). Influenza (http://www.who.int/immunization/topics/influenza/en/). Accessed 7 February 2017.
2. Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am RKI Stand: August 2016 (recommendations of standing committee on vaccination at RKI, August 2016). Epidemiologisches Bulletin 2016; 34: 301340.
3. Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am RKI Stand: August 2013 (recommendations of standing committee on vaccination at RKI, August 2013). Epidemiologisches Bulletin 2013; 34: 313344.
4. Robert Koch-Institut. Stellungnahme der STIKO zur Anwendung von Influenza-Lebendimpfstoffen bei Kindern in der Saison 2016/2017 (standing committee on vaccination comments on the use of life attenuated influenza vaccines in children during season 2016/17). Epidemiologisches Bulletin 2016; 39: 442443.
5. Falkenhorst, G, et al. Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2–6 years in Germany. Bundesgesundheitsblatt 2013; 56: 15571564.
6. Grohskopf, LA, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recommendations and Reports 2016; 65: 154.
7. Paul Ehrlich-Institut. PEI Influenza (saisonal): Informationen zu den aktuellen Grippeimpfstoffen (Information on the current influenza vaccines) (http://www.pei.de/DE/infos/fachkreise/impfungen-impfstoffe/influenza-grippeimpfstoffe-saisonal/influenza-grippeimpfstoffe-node.html). Accessed 7 January 2017.
8. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season (http://www.who.int/influenza/vaccines/virus/recommendations/2012_13_north/en/). Accessed 4 September 2016.
9. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013-14 northern hemisphere influenza season (http://www.who.int/influenza/vaccines/virus/recommendations/2013_14_north/en/). Accessed 4 September 2016.
10. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season (http://www.who.int/influenza/vaccines/virus/recommendations/2014_15_north/en/). Accessed 4 September 2016.
11. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season (http://www.who.int/influenza/vaccines/virus/recommendations/2015_16_north/en/). Accessed 4 September 2016.
12. Weinberg, GA, Szilagyi, PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. The Journal of Infectious Diseases 2010; 201: 16071610.
13. Kissling, E, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Eurosurveillance 2014; 19: 20701.
14. Kissling, E, Valenciano, M. Early influenza vaccine effectiveness results 2015-16: I-MOVE multicentre case-control study. Eurosurveillance 2016; 21: 30134.
15. Sullivan, SG, et al. Pooled influenza vaccine effectiveness estimates for Australia, 2012-2014. Epidemiology and Infection 2016; 144: 23172328.
16. Kelly, H, et al. Estimation of influenza vaccine effectiveness from routine surveillance data. PLoS ONE. 2009; 4: e5079.
17. Pebody, R, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Eurosurveillance 2015; 20: 30013.
18. Belongia, EA, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. The Lancet Infectious Diseases. 2016; 16: 942951.
19. Helmeke, C, et al. Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study. PLOS ONE 2015; 10: e0122910.
20. Haas, W. Influenza: Prävention, Diagnostik, Therapie und öffentliche Gesundheit (Prevention, Diagnostic, Therapy and Public Health). München: Elsevier Urban & Fischer, 2009, p. 24.
21. Swart, E, et al. Gute Praxis Sekundardatenanalyse (GPS): Leitlinien und Empfehlungen (good practice of secondary data analysis (GPS): guidelines and recommendations). Gesundheitswesen 2015; 77: 120126.
22. Robert Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2012/13 (Epidemiological report on influenza in Germany season 2012/13) (https://influenza.rki.de/Saisonberichte/2012.pdf). Accessed 20 August 2017.
23. Robert Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2013/14 (Epidemiological report on influenza in Germany in 2013/14) (https://influenza.rki.de/Saisonberichte/2013.pdf). Accessed 20 August 2017.
24. Robert Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2014/15 (Epidemiological report on influenza in Germany season 2014/15) (https://influenza.rki.de/Saisonberichte/2014.pdf). Accessed 20 August 2017.
25. Robert Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2015/16 (Epidemiological report on influenza season 2015/16) (https://influenza.rki.de/Saisonberichte/2015.pdf). Accessed 20 August 2017.
26. Nohynek, H, et al. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds – a nationwide cohort study Finland, influenza season 2015/16. Eurosurveillance 2016; 21: 30346.
27. Pebody, R. Influenza vaccine effectiveness in adults and children in primary care in the UK: provisional end-of-season results 2015-16 (https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/530756/Influenza_vaccine_effectiveness_in_primary_care_in_children.pdf). Accessed 20 October 2016.
28. Centers for Disease Control and Prevention (CDC). ACIP votes down use of LAIV for 2016-2017 flu season (http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html). Accessed 20 October 2016.
29. Landesamt für Verbraucherschutz Sachsen-Anhalt. Effektivität der Influenza-Impfstoffe bei Kindern in Sachsen-Anhalt und Niedersachsen 2015/16 (Effectiveness of the influenza vaccine in children in Saxony-Anhalt and Lower Saxony 2015/16) (http://www.verbraucherschutz.sachsen-anhalt.de/fileadmin/Bibliothek/Politik_und_Verwaltung/MS/LAV_Verbraucherschutz/hygiene/influenza/Effektivitaet_der_Influenzaimpfstoffe_2015-16.pdf). Accessed 12 February 2017.
30. Belongia, EA, et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Review of Vaccines 2017; 16: 114.
31. Smith, DJ, et al. Variable efficacy of repeated annual influenza vaccination. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 1400114006.
32. Skowronski, DM, et al. A perfect storm: impact of genomic variation and serial vaccination on Low influenza vaccine effectiveness during the 2014-2015 season. Clinical Infectious Diseases 2016; 63: 2132.
33. Skowronski, DM, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Eurosurveillance 2015; 20: pii=21022.
34. Jackson, ML, Rothman, KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine 2015; 33: 13131316.
35. Orenstein, EW, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. International Journal of Epidemiology 2007; 36: 623631.
36. De Serres, G, et al. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Eurosurveillance 2013; 18: pii=20585.

Keywords

Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012–2016

  • A. MÖHL (a1), L. GRÄFE (a2), C. HELMEKE (a2), D. ZIEHM (a1), M. MONAZAHIAN (a1), H.-M. IRMSCHER (a2) and J. DREESMAN (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed